58.28
1.14%
-0.67
Keros Therapeutics Inc stock is currently priced at $58.28, with a 24-hour trading volume of 343.76K.
It has seen a -1.14% decreased in the last 24 hours and a -9.22% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $59.48 pivot point. If it approaches the $57.62 support level, significant changes may occur.
Keros Therapeutics Inc Stock (KROS) Financials Data
Keros Therapeutics Inc (KROS) Net Income 2024
KROS net income (TTM) was -$152.99 million for the quarter ending December 31, 2023, a -46.15% decrease year-over-year.
Keros Therapeutics Inc (KROS) Cash Flow 2024
KROS recorded a free cash flow (TTM) of -$126.97 million for the quarter ending December 31, 2023, a -78.07% decrease year-over-year.
Keros Therapeutics Inc (KROS) Earnings per Share 2024
KROS earnings per share (TTM) was -$5.20 for the quarter ending December 31, 2023, a -25.30% decline year-over-year.
Keros Therapeutics Inc Stock (KROS) Latest News
Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference
GlobeNewswire Inc.
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
GlobeNewswire Inc.
Keros Therapeutics, Inc. (KROS) is on the Move, Here's Why the Trend Could be Sustainable
Zacks Investment Research
Does Keros Therapeutics, Inc. (KROS) Have the Potential to Rally 35.66% as Wall Street Analysts Expect?
Zacks Investment Research
Recent Price Trend in Keros Therapeutics, Inc. (KROS) is Your Friend, Here's Why
Zacks Investment Research
Wall Street Analysts Predict a 45.35% Upside in Keros Therapeutics, Inc. (KROS): Here's What You Should Know
Zacks Investment Research
About Keros Therapeutics Inc
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or FOP, and is currently in a Phase 1 clinical trial; and KER-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or PAH. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.
Cap:
|
Volume (24h):